2,886,586.0
New Delhi: The members of the Subject Expert Committee (SEC) of the Drugs Controller General of India (DCGI), responsible for recommending vaccines for approval, changed their minds about Bharat Biotech’s Covaxin over the course of meetings on three days December 30, January 1 and January 2. Experts have criticised the approval for Covaxin, saying that it was given without adequate data.
The All India Drugs Action Network (AIDAN) activist group said it was “perplexed” at the abrupt change in the SEC’s thinking. “Over the course of meetings over the days, the hesitation of the SEC in granting REU (restricted emergency use) approval in the absence of any efficacy data has been documented,” it said in a statement.
India News: The government will roll out the Covid-19 vaccine next week, with health secretary Rajesh Bhushan saying this was set to happen within 10 days of emer